FGL-1 is a novel hepatokine mainly expressed in the liver under normal physiological conditions, but whose levels are increased by high fat conditions and lead to lipid accumulation and inflammation, which in turn trigger the development of NAFLD, diabetes, and obesity (61). This evidence concerns the gene FGL1 and metabolic dysfunction-associated steatotic liver disease.